What's Happening?
Cordis has unveiled groundbreaking results from the SELUTION DeNovo and SELUTION4ISR trials at the Transcatheter Cardiovascular Therapeutics 2025 symposium. These trials evaluated the SELUTION SLR Drug-Eluting
Balloon (DEB) as a treatment for coronary artery disease, specifically in de novo lesions and in-stent restenosis (ISR). The SELUTION DeNovo trial, the largest of its kind, demonstrated that the DEB strategy is non-inferior to drug-eluting stents (DES) in treating de novo lesions. Similarly, the SELUTION4ISR trial confirmed the DEB's non-inferiority in treating ISR compared to standard care. These findings suggest that the SELUTION SLR DEB could serve as a viable alternative to traditional stenting methods.
Why It's Important?
The results from these trials represent a significant advancement in the treatment of coronary artery disease, offering a new approach that could reduce the reliance on stents. This is particularly important as it provides a less invasive option with potentially fewer complications associated with stent implantation. The SELUTION SLR DEB's ability to deliver effective treatment without additional metal layers could lead to improved patient outcomes and reduced long-term healthcare costs. The success of these trials positions Cordis as a leader in cardiovascular innovation, potentially influencing future treatment protocols and expanding the use of drug-eluting balloons in clinical practice.
What's Next?
Cordis is expected to leverage the positive trial results to seek FDA approval for the SELUTION SLR DEB's use in treating coronary artery disease. The company may also continue to conduct further studies to explore additional applications and long-term benefits of the DEB technology. As the medical community digests these findings, there may be increased interest in adopting this new treatment approach, potentially leading to changes in clinical guidelines and practices. Cordis's ongoing commitment to innovation suggests that further advancements in cardiovascular care could be on the horizon.
